國立虎尾科技大學 |

Liver Intra-arterial PRRT with 111In-Octreotide = The Tumoricidal Efficacy of 111In Auger Electron Emission /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Liver Intra-arterial PRRT with 111In-Octreotide/ edited by Georgios S. Limouris.
Reminder of title:	The Tumoricidal Efficacy of 111In Auger Electron Emission /
other author:	Limouris, Georgios S.
Description:	XIII, 270 p. 130 illus., 124 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Nuclear medicine. -
Online resource:	https://doi.org/10.1007/978-3-030-70773-6
ISBN:	9783030707736

Liver Intra-arterial PRRT with 111In-Octreotide = The Tumoricidal Efficacy of 111In Auger Electron Emission /
Liver Intra-arterial PRRT with 111In-OctreotideThe Tumoricidal Efficacy of 111In Auger Electron Emission /[electronic resource] :edited by Georgios S. Limouris. - 1st ed. 2021. - XIII, 270 p. 130 illus., 124 illus. in color.online resource.

The efficacy of auger and internal conversion electron emission 0f in-111 to treat neuroendocrine tumors -- Somatostatin -- Gastro-entero-pancreatic neuroendocrine tumors -- [111in-dtpa0-d-phe1] - octreotide: the ligand -the receptor-label -- Regulations and requirements of hospitals performing radio-infusions -- Intravenous radio-peptide infusion with in-octreotide -- Intra-arterial radio-peptide infusion -- Radio-peptide infusions after implementation of an intra-arterial port system -- US, CT and MRI for the evaluation of patients with neuroendocrine tumors -- Angiographic anatomy on the course of liver intra-arterial infusion -- Liver radio-infusions: identifying anatomic variants -- Dosimetry and dose calculation: its necessity in radio-peptide therapy -- Evaluation and assessment of the radio-peptide treatment efficacy -- Intra-venous radio-peptide infusions with in-octreotide for the treatment of bronchial carcinoids -- Intra-arterial radio - peptide infusions for the treatment of colorectal carcinomas -- Intra-arterial radio-peptide infusions for the treatment of paragangliomas -- Intra-arterial radio-peptide infusions for the treatment of brain meningiomas -- Surgery in neuroendocrine tumors -- Cytoreductive surgery combined with intraperitoneal [111in-dtpa0– d-phe1]-octreotide infusions in neuroendocrine character metastases -- Patients survival followed intra-arterial versus intravenous infusions -- Complications and side effects on the course of liver-radio-infusions -- Progression free survival and response rate in neuroendocrine liver–metastasized patients, treated with in-111 octreotide -- Therapy response vs variability of tumor size, absorbed dose, and ki-67 index after in-111 octreotide intra-arterial infusions.

This book describes in detail a clinical project that reveals the tumoricidal efficacy of Auger and internal conversion electrons, emitted from n.c.a. 111In and implemented in oncology as a treating armamentarium for peptide receptor radionuclide therapy (PRRT), targeting small size (ø ≤ 20 mm) tumors and micro-metastases. The keen interest in n.c.a. 111In began when it was observed that its Auger electron emission could be highly radiotoxic, due to its high LET when it decayed in the vicinity of cellular DNA. The somatostatin analog octreotide, labeled with [111In-diethylenetriaminepentaacetic acid (DTPA0-D-Phe1)] is an established diagnostic agent for the imaging of somatostatin receptor-positive neuro- (or non-neuro) endocrine tumors. It relies on receptor-mediated binding, internalization and installation in the lysosomes in the proximity of the nucleus; administered in large doses, loco-regionally, via the feeding artery of solid tumors, can be highly radiotoxic if they over-express somatostatin receptors, mainly of the sst2 histotype. The book compares the results between i.v. and i.a. implementation in more than 80 patients after over 800 i.a. infusions in neuroendocrine tumors, meningiomas, paragangliomas and colorectal carcinomas in a single Institute (Aretaieion University Hospital) and encourages the i.a. way, leading to “tumor melting”, while minimizing the toxicity to healthy peritumoral liver tissue and critical organs (kidneys and bone marrow). The volume is an invaluable tool for nuclear medicine physicians, interventional radiologists and oncologists dealing with radiopeptide therapies. .

ISBN: 9783030707736

Standard No.: 10.1007/978-3-030-70773-6doiSubjects--Topical Terms:

673902
Nuclear medicine.

LC Class. No.: R895-920

Dewey Class. No.: 616.07548

Liver Intra-arterial PRRT with 111In-Octreotide = The Tumoricidal Efficacy of 111In Auger Electron Emission /
LDR:04800nam a22003975i 4500 001 1054997
003 DE-He213
005 20210622092032.0
007 cr nn 008mamaa
008 220103s2021 gw | s |||| 0|eng d
020 $a 9783030707736 $9 978-3-030-70773-6
024 7 $a 10.1007/978-3-030-70773-6 $2 doi
035 $a 978-3-030-70773-6
050 4 $a R895-920
072 7 $a MMN $2 bicssc
072 7 $a MED080000 $2 bisacsh
072 7 $a MKR $2 thema
082 0 4 $a 616.07548 $2 23
245 1 0 $a Liver Intra-arterial PRRT with 111In-Octreotide $h [electronic resource] : $b The Tumoricidal Efficacy of 111In Auger Electron Emission / $c edited by Georgios S. Limouris.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XIII, 270 p. 130 illus., 124 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a The efficacy of auger and internal conversion electron emission 0f in-111 to treat neuroendocrine tumors -- Somatostatin -- Gastro-entero-pancreatic neuroendocrine tumors -- [111in-dtpa0-d-phe1] - octreotide: the ligand -the receptor-label -- Regulations and requirements of hospitals performing radio-infusions -- Intravenous radio-peptide infusion with in-octreotide -- Intra-arterial radio-peptide infusion -- Radio-peptide infusions after implementation of an intra-arterial port system -- US, CT and MRI for the evaluation of patients with neuroendocrine tumors -- Angiographic anatomy on the course of liver intra-arterial infusion -- Liver radio-infusions: identifying anatomic variants -- Dosimetry and dose calculation: its necessity in radio-peptide therapy -- Evaluation and assessment of the radio-peptide treatment efficacy -- Intra-venous radio-peptide infusions with in-octreotide for the treatment of bronchial carcinoids -- Intra-arterial radio - peptide infusions for the treatment of colorectal carcinomas -- Intra-arterial radio-peptide infusions for the treatment of paragangliomas -- Intra-arterial radio-peptide infusions for the treatment of brain meningiomas -- Surgery in neuroendocrine tumors -- Cytoreductive surgery combined with intraperitoneal [111in-dtpa0– d-phe1]-octreotide infusions in neuroendocrine character metastases -- Patients survival followed intra-arterial versus intravenous infusions -- Complications and side effects on the course of liver-radio-infusions -- Progression free survival and response rate in neuroendocrine liver–metastasized patients, treated with in-111 octreotide -- Therapy response vs variability of tumor size, absorbed dose, and ki-67 index after in-111 octreotide intra-arterial infusions.
520 $a This book describes in detail a clinical project that reveals the tumoricidal efficacy of Auger and internal conversion electrons, emitted from n.c.a. 111In and implemented in oncology as a treating armamentarium for peptide receptor radionuclide therapy (PRRT), targeting small size (ø ≤ 20 mm) tumors and micro-metastases. The keen interest in n.c.a. 111In began when it was observed that its Auger electron emission could be highly radiotoxic, due to its high LET when it decayed in the vicinity of cellular DNA. The somatostatin analog octreotide, labeled with [111In-diethylenetriaminepentaacetic acid (DTPA0-D-Phe1)] is an established diagnostic agent for the imaging of somatostatin receptor-positive neuro- (or non-neuro) endocrine tumors. It relies on receptor-mediated binding, internalization and installation in the lysosomes in the proximity of the nucleus; administered in large doses, loco-regionally, via the feeding artery of solid tumors, can be highly radiotoxic if they over-express somatostatin receptors, mainly of the sst2 histotype. The book compares the results between i.v. and i.a. implementation in more than 80 patients after over 800 i.a. infusions in neuroendocrine tumors, meningiomas, paragangliomas and colorectal carcinomas in a single Institute (Aretaieion University Hospital) and encourages the i.a. way, leading to “tumor melting”, while minimizing the toxicity to healthy peritumoral liver tissue and critical organs (kidneys and bone marrow). The volume is an invaluable tool for nuclear medicine physicians, interventional radiologists and oncologists dealing with radiopeptide therapies. .
650 0 $a Nuclear medicine. $3 673902
650 0 $a Oncology . $3 1253469
650 0 $a Interventional radiology . $3 1254011
650 0 $a Surgery. $3 644132
650 1 4 $a Nuclear Medicine. $3 673045
650 2 4 $a Oncology. $3 593951
650 2 4 $a Interventional Radiology. $3 673687
700 1 $a Limouris, Georgios S. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1360143
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030707729
776 0 8 $i Printed edition: $z 9783030707743
776 0 8 $i Printed edition: $z 9783030707750
856 4 0 $u https://doi.org/10.1007/978-3-030-70773-6
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)